Can-Fite BioPharma Ltd. Files 6-K, Incorporates Press Release
Ticker: CANF · Form: 6-K · Filed: Oct 9, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Oct 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, registration-statement, press-release
TL;DR
Can-Fite BioPharma filed a 6-K on Oct 9, 2024, incorporating a press release into existing S-8 and F-3 filings. No new financials.
AI Summary
On October 9, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 and Form F-3. This filing does not appear to contain new financial data but rather updates existing filings.
Why It Matters
This filing indicates an update to Can-Fite BioPharma's SEC filings, potentially affecting how investors view their ongoing registration statements and disclosures.
Risk Assessment
Risk Level: low — The filing is procedural, incorporating existing information into other filings, and does not appear to introduce new material risks or financial changes.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- October 9, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form S-8 (document) — Incorporated filing
- Form F-3 (document) — Incorporated filing
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information to the SEC and incorporate by reference a press release into the registrant's existing Registration Statements on Form S-8 and Form F-3.
When was this Form 6-K filed?
This Form 6-K was filed on October 9, 2024.
Which specific registration statements are being updated by this filing?
This filing incorporates information into Can-Fite BioPharma's Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000, and 333-281872).
Does this filing introduce new financial information?
Based on the provided text, this filing primarily incorporates a press release into existing filings and does not appear to introduce new financial data.
What is the company's principal executive office address?
The company's principal executive offices are located at 26 Ben Gurion Street, Ramat Gan 5257346, Israel.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-10-09 07:03:13
Filing Documents
- ea0217148-6k_canfite.htm (6-K) — 10KB
- ea021714801ex99-1_canfite.htm (EX-99.1) — 12KB
- 0001213900-24-086392.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 9, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2